Ironwood Pharmaceuticals, Inc. Stock price

Equities

IRWD

US46333X1081

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 01:17:11 2024-03-28 pm EDT 5-day change 1st Jan Change
8.785 USD +1.91% Intraday chart for Ironwood Pharmaceuticals, Inc. -2.33% -22.90%
Sales 2024 * 448M Sales 2025 * 494M Capitalization 1.35B
Net income 2024 * 106M Net income 2025 * 139M EV / Sales 2024 * 3.01 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 2.73 x
P/E ratio 2024 *
11.1 x
P/E ratio 2025 *
9.8 x
Employees 267
Yield 2024 *
-
Yield 2025 *
-
Free-Float 97.92%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Ironwood Pharmaceuticals, Inc.

1 day+3.61%
1 week-5.38%
Current month-8.59%
1 month-43.21%
3 months-25.11%
6 months-10.49%
Current year-24.65%
More quotes
1 week
8.21
Extreme 8.21
9.10
1 month
8.21
Extreme 8.21
11.00
Current year
8.21
Extreme 8.21
15.70
1 year
8.08
Extreme 8.075
15.70
3 years
8.08
Extreme 8.075
15.70
5 years
7.91
Extreme 7.91
15.70
10 years
7.35
Extreme 7.35
21.20
More quotes
Managers TitleAgeSince
Chief Executive Officer 66 08-12-31
Director of Finance/CFO 46 21-12-05
Chief Tech/Sci/R&D Officer - 13-12-31
Members of the board TitleAgeSince
Director/Board Member 54 20-11-08
Director/Board Member 66 20-12-02
Director/Board Member 69 19-12-31
More insiders
Date Price Change Volume
24-03-28 8.82 +2.32% 1 330 815
24-03-27 8.62 +3.61% 3,281,085
24-03-26 8.32 -1.07% 2,963,933
24-03-25 8.41 -3.11% 3,612,818
24-03-22 8.68 -3.88% 3,648,957

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Ironwood Pharmaceuticals, Inc. is a gastrointestinal (GI) healthcare company, which is advancing the treatment of GI diseases and redefining the standard of care for GI patients. It is develops and commercializes GI product opportunities in areas of significant unmet need, leveraging its demonstrated expertise and capabilities in GI diseases. LINZESS (linaclotide), its commercial product, in a class of GI medicines called guanylate cyclase type C agonists (GC-C agonists) and is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC). LINZESS is available to adult men and women suffering from IBS-C or CIC in the United States and Mexico, IBS-C or chronic constipation in Japan, and IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC in Canada, and to adult men and women suffering from IBS-C in certain European countries.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
8.62 USD
Average target price
18 USD
Spread / Average Target
+108.82%
Consensus
  1. Stock
  2. Equities
  3. Stock Ironwood Pharmaceuticals, Inc. - Nasdaq